194 results about "Psoriatic disease" patented technology

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.

A method of treating psoriatic arthritis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20 / 50 / 70, PASI70 / 90 / 100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI / dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 improvement as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

The invention discloses a method and a system for constructing an intelligent typing diagnosis model of psoriasis. The method comprises the following steps: S1, collecting pairing multi-modal data of a psoriasis patient whose fingernails are not tired, wherein the pairing multi-modal data comprises clinical information, scanning electron microscope images of fingernail surface morphology and infrared spectrum data of fingernail protein; s2, constructing a clinical feature encoder; s3, constructing a spectral feature encoder; s4, constructing an image feature encoder; s5, constructing a hierarchical fusion module; and S6, three loss function components are constructed, multi-objective optimization of the model is realized, and a total loss function is adopted to carry out model training. According to the method, the clinical information, the scanning electron microscope image of the nail surface morphology and the infrared spectrum data of the nail protein are integrated, and the multi-mode deep learning technology is combined, so that early recognition and prediction of psoriatic arthritis in a psoriasis patient are realized.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The invention relates to the technical field of disease risk prediction and precision medical treatment, in particular to an establishment method and application of a late-onset psoriasis risk prediction model, and the method comprises the following steps: (1) collecting lifestyle data, serum metabolite data, clinical characteristics and polygene risk scores of a subject; (2) constructing a healthy lifestyle score according to the lifestyle data; (3) screening metabolites significantly related to the healthy lifestyle by using a multiple linear regression model; (4) screening metabolites significantly related to the risk of late psoriasis by using a Cox regression model; (5) screening a key metabolite set by adopting an elastic network regression model; and (6) inputting the sample features into a machine learning model to obtain a late-onset psoriasis risk prediction model. According to the method, the prediction accuracy is high, the AUC can reach 0.86 by combining the lifestyle, serum metabolites and genetic risks, and the method is obviously superior to a prediction method only depending on clinical characteristics or genetic information.

The invention provides a compound shown in a formula I or pharmaceutically acceptable salts, stereoisomers, isotope derivatives, solvates (such as hydrates), prodrugs, metal chelates, crystal forms or metabolites of the compound and application of the compound in the field of medicine. The compound can be used for treating and / or preventing psoriasis diseases, especially propafenone. The invention also finds that under the condition of the same administration dosage, the effect of smearing administration on treating psoriasis diseases is better than that of injection administration. Compared with a flecainib ointment with a similar anti-arrhythmia function, the propafenone ointment disclosed by the invention has a better effect on treating psoriasis diseases.

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, R1-R4, n and m have the meanings given in the specification. The compounds of formula I exhibit GPR183 antagonistic activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases to which GRP183 antagonists are applicable, such as chronic pain, such as osteoarthritis, chronic lumbago, neuropathic pain, and immune system diseases, such as inflammatory bowel diseases, such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, and the like. , such as asthma and psoriasis.

The invention is related to methods of treatment of active psoriatic arthritis (PsA). In certain embodiments, the invention provides pharmaceutical compositions of izokibep and uses thereof for treatment of active psoriatic arthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

Provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein (I) can inhibit TNFR1 and is expected to be useful as a therapeutic agent for treating, for example, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa.The present disclosure also provides a pharmaceutical composition comprising the compound disclosed herein or a pharmaceutically acceptable salt thereof.The present disclosure also relates to a method of using the compound or a pharmaceutically acceptable salt thereof in the treatment and prevention of inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa, as well as a method of preparing a medicament for this purpose. [Formula 1] TIFF0007746628000195.tif82167

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

The present disclosure relates to inhibitors of miR-574-5p (SEQ ID NO: 1) for use in intra-articular treatment of a disease selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, gout, juvenile arthritis, systemic lupus erythematosus (SLE), Sjögren's syndrome and osteoporosis.

The present invention pertains to a method or a pharmaceutical composition of new ovatodiolide derivative compounds, AR100-RA1-Cys and AR100-RA1-ST, which have shown unexpected effects in treating autoimmune diseases, characterized by hepatocellular inflammation, such as autoimmune hepatitis, diabetes mellitus type 1, Sjogren's syndrome, multiple sclerosis and psoriasis. Also provided are the synthetic processes for compound preparation.

The disclosure relates to methods of treating psoriatic arthritis in a patient comprising administering an anti-IL-23p19 antibody hum13B8-b to the patient. The disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b for the treatment of psoriatic arthritis in a patient. The disclosure further relates to the use of an anti- IL-23p19 antibody hum13B8-b for the manufacture of a medicament for treating psoriatic arthritis in a patient. The disclosure further relates to methods, compositions, or uses wherein administration of hum13B8-b results in minimal or no serious or other side effects after up to at least about 208 weeks.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of various conditions, including but not limited to congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by elevated leptin signaling.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The application discloses a kind of based on ensemble learning's psoriasis image intelligent identification method and device;Among them, the method includes: obtaining image data to be identified;The image data to be identified is input into the feature extraction network in ensemble learning model and is extracted feature extraction processing, and obtains extraction image feature;Based on extraction image feature in the image segmentation network in the ensemble learning model, the image to be identified is carried out image segmentation processing, and obtains segmentation image data;Based on the segmentation image data and the image data to be identified are spliced processing, and based on splicing image, psoriasis image classification identification is carried out.In the embodiment of the application, accurate classification identification of psoriasis image is realized, and better auxiliary doctor is diagnosed with psoriasis.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

This disclosure provides substituted 6-imidazopyridazine compounds for the modulation of IL-17A and pharmaceutical compositions thereof. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, or ankylosing spondylitis.

The disclosure herein provides substituted 6-imidazopyridazine compounds, and pharmaceutical compositions thereof, for use in the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis or ankylosing spondylitis.

The invention relates to a clioquinol for use in the prevention or treatment of psoriasis or of inflammatory bowel disease (IBD).